"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA Hematology Oncology conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 5 clinical trials were completed, i.e. on average, 500% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UCLA Hematology Oncology" are "Breast Neoplasms" (1 trials), "HER2+ Metastatic Breast Cancer (MBC)" (1 trials), "Melanoma" (1 trials), "Metastatic Colorectal Carcinoma" (1 trials) and "Non Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "UCLA Hematology Oncology" in a lesser frequency.

Most popular intervention types in "UCLA Hematology Oncology" are "Drug" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Alclometasone cream" (1 trials), "Bevacizumab" (1 trials), "Dacomitinib" (1 trials) and "Doxycycline" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Hematology Oncology" are 4 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Hematology Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in UCLA Hematology Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Hematology Oncology, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".